Drug

Dinoprostone

In clinical development

ClassProstaglandin E2 receptor agonistEmerging researchLate-stage developmentRising momentum

Also known as (15S)-prostaglandin E2, Cervidil, Dinoprostone Prostaglandin E2, PGE-2+12 more

(15S)-prostaglandin E2, Cervidil, Dinoprostone Prostaglandin E2, PGE-2, PGE2, Prepidil, Prostaglandin E2, Prostaglandin PGE2, Prostin E2, Dinoproston, Dinoprostona, (5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate, (5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprosta-5,13-dienoate, (E,Z)-(1R,2R,3R)-7-(3-Hydroxy-2-((3S)-(3-hydroxy-1-octenyl))-5-oxocyclopentyl)-5-heptenoic acid, (Z)-7-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)hept-5-enoic acid, Dinoprostonum.

RxNorm3478 ChEMBLCHEMBL548 ATCG02AD02UNIIK7Q1JQR04M

Research papers

Active clinical trials

Protein targets

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Comparison of Vaginal PGE2 (Dinoprostone) and Vaginal Misoprostol for Induction of Labour in Primigravid Term Pregnancy

Clinical trial2026-04-29Primary completion · ClinicalTrials.gov

Evaluation of Stripping for Cervical Ripening - A Randomized Controlled Study

Clinical trial2026-04-15Results expected Q4 2027 · ClinicalTrials.gov

The Effectiveness and Safety of Double-balloon Versus Vaginal Prostaglandin for Cervical Ripening in Women With Low-risk Pregnancies: A Randomized Controlled Trial (DOBA-PRO)

Clinical trial2025-08-01Primary completion · ClinicalTrials.gov

Prostaglandin E2-EP2/EP4 signaling induces immunosuppression in human cancer by impairing bioenergetics and ribosome biogenesis in immune cells.

Research2024-11-01Nature communications

Gemeprost Versus Dinoprostone in the Medical Management of First Trimester Miscarriages: a Randomized Controlled Study

Clinical trial2024-10-28Completed · ClinicalTrials.gov

The antioxidant N-acetyl cysteine inhibits cytokine and prostaglandin release in human fetal membranes stimulated ex vivo with lipoteichoic acid or live group B streptococcus.

Research2024-01-01American journal of reproductive immunology (New York, N.Y. : 1989)

Pro-tumor Tfh2 cells induce detrimental IgG4 production and PGE2-dependent IgE inhibition in pancreatic cancer.

Research2023-09-28EBioMedicine

Primary hypertrophic osteoarthropathy: genetics, clinical features and management.

Research2023-08-29Frontiers in endocrinology

Update on the pathological roles of prostaglandin E2 in neurodegeneration in amyotrophic lateral sclerosis.

Research2023-06-19Translational neurodegeneration

Induction of Labour With Dinoprostone vs. Expectant Management After Prelabour Rupture of Membranes at Term

Clinical trial2023-06-01Primary completion · ClinicalTrials.gov

Preoperative Vaginal Dinoprostone Versus Misoprostone to Decrease Bleeding During Abdominal Myomectomy

Clinical trial2023-02-20Completed · ClinicalTrials.gov

Labour Induction With the Propess Vaginal Delivery System vs. Labour Induction With the Prostin Vaginal Tablet in Case of a Prelabour Rupture of Membranes. PESTIBOR Randomized Controlled Trial

Clinical trial2023-01-01Primary completion · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Dinoprostone

Aliases & brands

(15S)-prostaglandin E2CervidilDinoprostone Prostaglandin E2PGE-2PGE2PrepidilProstaglandin E2Prostaglandin PGE2Prostin E2DinoprostonDinoprostona(5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate(5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprosta-5,13-dienoate(E,Z)-(1R,2R,3R)-7-(3-Hydroxy-2-((3S)-(3-hydroxy-1-octenyl))-5-oxocyclopentyl)-5-heptenoic acid(Z)-7-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)hept-5-enoic acidDinoprostonum

RxNorm CUI

3478

ChEMBL ID

CHEMBL548

ATC codes

G02AD02

UNII

K7Q1JQR04M

Primary mechanism

Prostaglandin E2 receptor agonist

Pharmacology & targets

4 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

Prostaglandin E2 receptor EP1 subtype

PTGER1 · P34995

AGONISTProstaglandin E2 receptor agonist

Prostaglandin E2 receptor EP4 subtype

PTGER4 · P35408

AGONISTProstaglandin E2 receptor agonist

Prostaglandin E2 receptor EP2 subtype

PTGER2 · P43116

AGONISTProstaglandin E2 receptor agonist

Prostaglandin E2 receptor EP3 subtype

PTGER3 · P43115

AGONISTProstaglandin E2 receptor agonist

Clinical trials

53 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

registered trials across all phases

LATEST COMPLETION 2024

Active studies

Recruiting

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 53

Phase 1 / 21Phase 25Phase 2 / 31Phase 313Phase 414Phase N / A19

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Induction of Labour With Dinoprostone vs. Expectant Management After Prelabour Rupture of Membranes at Term

Unknown statusPH IVUniversity Medical Centre Ljubljanan=702023

Labour Induction With the Propess Vaginal Delivery System vs. Labour Induction With the Prostin Vaginal Tablet in Case of a Prelabour Rupture of Membranes. PESTIBOR Randomized Controlled Trial

Unknown statusPH IVUniversity Medical Centre Mariborn=5262023

Comparison of Intracervical and Intravaginal Application of Prostaglandin E2 for Induction of Labour in Term Pregnancies With Unfavourable Cervix

CompletedPH IVClinical Hospital Merkurn=2122020

Vaginal Dinoprostone Versus Vaginal Misoprostol Prior to Diagnostic Office Hysteroscopy in Postmenopausal Patients: a Randomized Controlled Trial

CompletedPH IVCairo Universityn=1502020

Effect of Self-Administered Vaginal Dinoprostone on Pain Perception During Copper Intrauterine Device Insertion in Parous Women: a Randomized Controlled Trial

CompletedPH IVCairo Universityn=1602020

Recent completions

Trials that read out recently, adding to the completed evidence base.

Gemeprost Versus Dinoprostone in the Medical Management of First Trimester Miscarriages: a Randomized Controlled Study

CompletedPH IINational University of Malaysian=1012024

Preoperative Vaginal Dinoprostone Versus Misoprostone to Decrease Bleeding During Abdominal Myomectomy

CompletedPH IIIBeni-Suef Universityn=902023

Premature Rupture of Membranes at Term With an Unfavorable Cervix (Bishop Score<6): Comparison of Oxytocin, Dinoprostone Induction and Expectant Management

CompletedN/ARambam Health Care Campusn=4582022

Comparison of Cervical Ripening Balloon Versus 2nd Dinoprostone Insert for Labor Induction in Women With a Failed 1st Attempt of Induction With Dinoprostone.

CompletedN/ARambam Health Care Campusn=1442021

A Randomised Controlled Trial of a Synthetic Osmotic Cervical Dilator for Induction of Labour in Comparison to Dinoprostone Vaginal insErt: the SOLVE Trial

CompletedPH IIIBirmingham Women's NHS Foundation Trustn=6742021

A Comparison Between Labor Induction With Dinoprostone and a Cervical Ripening Balloon in Women With a BMI>30 as Oppose With a BMI<30.

CompletedN/ARambam Health Care Campusn=1642020

Research activity

7 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time

19962024

Most influential

T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines.

The Journal of experimental medicine · 1996 · 1,089 cites

Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death.

Nature communications · 2020 · 205 cites

Prostaglandin E2-EP2/EP4 signaling induces immunosuppression in human cancer by impairing bioenergetics and ribosome biogenesis in immune cells.

Nature communications · 2024 · 41 cites

Update on the pathological roles of prostaglandin E2 in neurodegeneration in amyotrophic lateral sclerosis.

Translational neurodegeneration · 2023 · 19 cites

Primary hypertrophic osteoarthropathy: genetics, clinical features and management.

Frontiers in endocrinology · 2023 · 19 cites

Pro-tumor Tfh2 cells induce detrimental IgG4 production and PGE2-dependent IgE inhibition in pancreatic cancer.

EBioMedicine · 2023 · 10 cites

Related drugs

4 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Acetylcysteine

Studied across 2 of the same disease areas as Dinoprostone in the shared literature.

2 shared diseases1 shared paper

Cisplatin

Studied across the same disease area as Dinoprostone in the shared literature.

1 shared disease1 shared paper

Deoxycytidine

Studied across the same disease area as Dinoprostone in the shared literature.

1 shared disease1 shared paper

Gemcitabine

Studied across the same disease area as Dinoprostone in the shared literature.

1 shared disease1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials